Short answer: not the way most owners assume.
If you run a well-regarded, responsive independent hormone or longevity clinic, the rise of national telehealth advertising is, on balance, working in your favor — not against you. Here’s the actual mechanism, because it isn’t obvious.
What the national brands are actually spending money on
Companies like Hone Health, TRT Nation, Marek Health, and Maximus have spent heavily on advertising hormone optimization directly to consumers, often at price points around $99–$450 a month, all-in.
That spend is doing something specific: it’s normalizing the idea that hormone decline is a treatable condition worth acting on, for men who might never have searched for it on their own.
A decade ago, asking a doctor about it was a niche, slightly embarrassed question. It isn’t anymore, and a meaningful share of the reason is that a handful of well-funded companies have spent years and a lot of money making it a normal one.
That’s advertising spend an independent clinic could never match. But it’s also advertising spend an independent clinic doesn’t have to match, because someone else is already paying for it — and the effect, more men willing to ask the question in the first place, benefits whoever eventually answers it.
Where the telehealth model runs out
A national telehealth brand can get a patient a prescription without much friction. What it structurally can’t offer is a real in-person relationship: a physical exam, in-person labs drawn locally, a provider who can adjust a protocol based on actually seeing the patient, and same-day access when something feels off.
For a meaningful share of men, the telehealth experience is where the awareness happens, but the decision to actually commit still lands somewhere in-person once they’re serious about it.
That’s the moment a local clinic competes for — and it isn’t won by outspending the national brand on ads. It’s won by being the option that answers first, feels legitimate, and makes the next step easy the moment someone reaches out. Which is a responsiveness problem, not an advertising budget problem.
A regulatory wrinkle worth watching, not betting on
Telehealth prescribing flexibilities that let providers prescribe certain controlled substances without an in-person exam first — the rule hormone therapy telehealth depends on — were extended through the end of 2026, with no permanent framework yet in place behind them. Nobody knows for certain what happens after that date.
It’s not something to plan a business around. But it is a real asymmetry worth naming: an all-remote model has a regulatory dependency an in-person clinic simply doesn’t carry.
What this means practically
Don’t try to out-advertise a company spending national-brand budgets on paid media — that’s not a fight an independent, single-location clinic can win, and it isn’t the fight that matters. The national brands are, in effect, running the awareness campaign for the entire category, for free, on your behalf.
The actual competitive question is much narrower and much more winnable: when that awareness turns into someone actually reaching out, are you the one who answers first? That’s the exact gap we’ve been measuring, and it’s the one independent clinics can close without spending a national brand’s marketing budget to do it.
Sources (checked 2026-08-22): DEA and HHS Extend Telemedicine Prescribing Flexibilities Through 2026 — Holland & Knight · HHS.gov — DEA Telemedicine Extension 2026 · competitor pricing checked against each brand’s own published rates as of August 2026.
